TissGeneSummary for POTED |
Gene summary |
Basic gene information | Gene symbol | POTED |
Gene name | POTE ankyrin domain family, member D | |
Synonyms | A26B3|ANKRD21|CT104.1|POTE|POTE-21|POTE21 | |
Cytomap | UCSC genome browser: 21q11.2 | |
Type of gene | protein-coding | |
RefGenes | NM_174981.3, | |
Description | ANKRD26-like family B member 3ANKRD26-like family B, member 3Expressed in prostate, ovary, testis, and placentaPOTE ankyrin domain family member Dankyrin repeat domain 21ankyrin repeat domain-containing protein 21cancer/testis antigen family 104, me | |
Modification date | 20141207 | |
dbXrefs | MIM : 607549 | |
HGNC : HGNC | ||
Ensembl : ENSG00000166351 | ||
HPRD : 09612 | ||
Vega : OTTHUMG00000074197 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_POTED | |
BioGPS: 317754 | ||
Pathway | NCI Pathway Interaction Database: POTED | |
KEGG: POTED | ||
REACTOME: POTED | ||
Pathway Commons: POTED | ||
Context | iHOP: POTED | |
ligand binding site mutation search in PubMed: POTED | ||
UCL Cancer Institute: POTED | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of POTED | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for POTED |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for POTED |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for POTED |
TissGeneSNV for POTED |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.M129I | SKCM | 2 |
p.E172K | SKCM | 2 |
p.H144Q | STAD | 1 |
p.F128L | GBM | 1 |
p.A119T | ESCA | 1 |
p.R136C | CESC | 1 |
p.R137* | SKCM | 1 |
p.V528L | LUAD | 1 |
p.R162K | SKCM | 1 |
p.L140Q | LUSC | 1 |
p.E542K | SKCM | 1 |
p.A119T | PCPG | 1 |
p.S112R | LUSC | 1 |
p.A127T | GBM | 1 |
p.K151R | OV | 1 |
p.D165Y | LUAD | 1 |
p.R524S | LUAD | 1 |
p.E502Q | BRCA | 1 |
p.G487E | UCS | 1 |
p.D335G | OV | 1 |
p.L540I | LGG | 1 |
p.E456K | CESC | 1 |
p.G239* | OV | 1 |
p.G487E | PAAD | 1 |
p.C109Y | LUAD | 1 |
p.R137Q | SKCM | 1 |
p.G487E | PRAD | 1 |
Top |
TissGeneCNV for POTED |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for POTED |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for POTED |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for POTED |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for POTED |
TissGeneDrug for POTED |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for POTED |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0006142 | Malignant neoplasm of breast | 1 | BeFree |
umls:C0029925 | Ovarian Carcinoma | 1 | BeFree |
umls:C0153594 | Malignant neoplasm of testis | 1 | BeFree |
umls:C0376358 | Malignant neoplasm of prostate | 1 | BeFree |
umls:C0600139 | Prostate carcinoma | 1 | BeFree |
umls:C0678222 | Breast Carcinoma | 1 | BeFree |
umls:C1140680 | Malignant neoplasm of ovary | 1 | BeFree |